Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

433
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
433
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

578
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
578

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plant-derived bioactive nutraceuticals mitigate aluminum-mediated neurotoxicity: Elucidated mechanisms and prospects.

Advances in neurotoxicology·2026
Same author

Impact of Low-Density Lipoprotein Cholesterol Levels on Atherosclerotic Vascular Changes: Analysis of Korean Treat Stroke to Target Trial.

Journal of stroke·2026
Same author

Post-stroke dizziness in anterior vs. posterior circulation ischemic stroke.

Frontiers in neurology·2026
Same author

Outcomes and Safety of Revascularization Approaches for Stroke Related to Isolated Vertebral Artery Occlusions (BRAVO).

Stroke·2026
Same author

Impact of Cervical Vertebral Artery Tortuosity on the Outcome After Mechanical Thrombectomy for Basilar Artery Occlusion.

Stroke (Hoboken, N.J.)·2026
Same author

Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System.

JAMA neurology·2026

Related Experiment Video

Updated: Mar 10, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

3.2K

Antithrombotic Therapy.

Sun U Kwon, Jong S Kim

    Frontiers of Neurology and Neuroscience
    |December 14, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Dual antiplatelet therapy may be needed for symptomatic intracranial atherosclerosis (ICAS) to prevent recurrent stroke. Studies show aspirin plus cilostazol may be more effective than aspirin alone, but more research is needed for optimal treatment strategies.

    More Related Videos

    Prehospital Thrombolysis: A Manual from Berlin
    05:52

    Prehospital Thrombolysis: A Manual from Berlin

    Published on: November 26, 2013

    22.5K
    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K

    Related Experiment Videos

    Last Updated: Mar 10, 2026

    An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
    07:50

    An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

    Published on: June 4, 2021

    3.2K
    Prehospital Thrombolysis: A Manual from Berlin
    05:52

    Prehospital Thrombolysis: A Manual from Berlin

    Published on: November 26, 2013

    22.5K
    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K

    Area of Science:

    • Neurology
    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Symptomatic cerebral atherosclerosis, including intracranial atherosclerosis (ICAS), carries a high risk of recurrent stroke.
    • Antithrombotic agents are standard treatment, but anticoagulants like warfarin increase bleeding risk without superior efficacy to aspirin.
    • Aspirin monotherapy may be insufficient due to ICAS progression and high stroke recurrence rates, suggesting a need for dual antiplatelet therapy.

    Purpose of the Study:

    • To review current evidence on antiplatelet therapy for symptomatic intracranial atherosclerosis (ICAS).
    • To evaluate the efficacy of dual antiplatelet agents compared to monotherapy in preventing ICAS progression and stroke recurrence.
    • To guide optimal medication strategies for patients with symptomatic ICAS.

    Main Methods:

    • Review of clinical trials and studies investigating antiplatelet agents for symptomatic intracranial atherosclerosis.
    • Analysis of data from trials such as TOSS (Trial of Cilostazol in Symptomatic Intracranial Stenosis) and comparisons with other regimens.
    • Evaluation of evidence from CHANCE (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events) and SAMMPRIS (Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis) trials.

    Main Results:

    • Aspirin plus cilostazol showed significantly better prevention of ICAS progression compared to aspirin monotherapy (6.7% vs. 28.8%).
    • While TOSS II found no significant difference in progression rates between aspirin plus cilostazol and aspirin plus clopidogrel, cilostazol group showed more favorable stenosis changes.
    • Recent CHANCE substudies indicated aspirin plus clopidogrel was not superior to aspirin monotherapy in ICAS patients, highlighting ongoing treatment uncertainties.

    Conclusions:

    • Dual antiplatelet therapy, potentially including cilostazol, may be beneficial in the early stages of symptomatic ICAS to prevent progression.
    • Current evidence is mixed regarding the superiority of dual antiplatelet agents over aspirin monotherapy, necessitating further clinical outcome-focused research.
    • Physicians should carefully consider patient-specific factors (stenosis degree, stroke risk, bleeding risk) and drug characteristics when selecting antiplatelet agents for ICAS.